Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-t.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

Pinterest delivers strong results, Apple looks for new chip manufacturers, and more

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript